ShroomSpy

ShroomSpy

Psilocybe Cyanescens

Psilocybe Cyanescens

Common Names: Wavy Cap, Blue Halos

About

Psilocybe cyanescens, commonly known as Wavy Cap Mushroom or Blue Halos, is a potent psychedelic mushroom known for its bluing reaction when bruised. It is primarily found in woodchips and has a strong hallucinogenic effect.

Physical Characteristics

Caps:

Medium-sized with a convex shape, initially caramel-brown and becoming light brown with age, sometimes with a wavy edge

Gills:

Initially pale yellow, maturing to dark brown

Psychoactive Effects

Hallucinogenic

Users may experience changes in visual perception such as enhanced colors, geometric patterns, or distortions.

Euphoric

Users often report intense feelings of joy and happiness

Helps With

Depression

Psilocybin has been shown to have antidepressant effects in clinical trials.

Anxiety

Psilocybin has been shown to have anxiolytic effects in clinical trials.

Addiction

Psilocybin has been shown to have anti-addictive effects in clinical trials.

PTSD

Psilocybin has been shown to have treat PTSD in clinical trials.

ADD ADHD

Psilocybin has been shown to improve attention and focus in clinical trials.

OCD

Psilocybin has been shown to reduce OCD symptoms in clinical trials.

Pain

Microdosing psilocybin has been shown to help with certain types of pain

Migraines

Research shows that psilocybin, the active compound in magic mushrooms, has potential therapeutic benefits for migraines.4 A small-scale study conducted by Yale School of Medicine found that a single dose of psilocybin reduced the likelihood of having a migraine attack in two weeks.

Potential Side Effects

Nausea

Can cause stomach discomfort and nausea, especially when eaten raw.

Medicinal Chemistry

Look Alike Species

Psilocybe Semilanceata

Specie:

Psilocybe semilanceata

Edibility:

Psychoactive

Differences:Psilocybe semilanceata has a more conical or bell-shaped cap and does not bruise blue as readily as Psilocybe cyanescens.

Mushroom Ratings

4.0

Based on 1 Review

5

★

4

★

3

★

2

★

1

★

Share your thoughts

If you've consumed this mushroom, share your thoughts with our community

Transformative Exploration with Psilocybe Cyanescens

01/29/2025

Anonymous

CalmContentCreativityEuphoricFocusReflectiveSpiritualVisualsDizzy
As a long-time explorer of the fascinating world of psychedelics, I recently had the chance to try the Psilocybe Cyanescens, commonly known as the WavyCap mushroom, and it was nothing short of transformative. From the very first moments after consumption, I felt a gradual wave of calm wash over me, easing the noise in my mind and creating a profound sense of focus. I was able to tap into my creativity like never before, and the insights I gained during the experience were eye-opening. Visually, the world around me transformed—colors appeared more vivid, and patterns danced in ways I had never noticed before. The reflective qualities of the experience allowed me to confront personal challenges with newfound clarity. The only side effect I encountered was a mild sense of dizziness that came and went, but honestly, it added to the experience rather than detracted from it. My consumption method was through dried fruit, which made it easy and enjoyable. Overall, I found that this mushroom truly enhances meditation and self-discovery, making it an invaluable ally on my journey of personal growth. Highly recommended for anyone looking to expand their consciousness!

References

  • Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?

    • Major depressive disorder (MDD) is one of the most disabling psychiatric disorders in the world. First-line treatments such as selective serotonin reuptake inhibitors (SSRIs) still have many limitations, including a resistance to treatment in 30% of patients and a delayed clinical benefit that is observed only after several weeks of treatment. Increasing clinical evidence indicates that the acute administration of psychedelic agonists of the serotonin 5-HT2A receptor (5-HT2AR), such as psilocybin, to patients with MDD induce fast antidepressant effects, which persist up to five weeks after the treatment.

    2024

  • Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

    • Mescaline, lysergic acid diethylamide (LSD), and psilocybin are classic serotonergic psychedelics. A valid, direct comparison of the effects of these substances is lacking. The main goal of the present study was to investigate potential pharmacological, physiological and phenomenological differences at psychoactive-equivalent doses of mescaline, LSD, and psilocybin. The present study used a randomized, double-blind, placebo-controlled, cross-over design to compare the acute subjective effects, autonomic effects, and pharmacokinetics of typically used, moderate to high doses of mescaline (300 and 500 mg), LSD (100 µg), and psilocybin (20 mg) in 32 healthy participants. A mescaline dose of 300 mg was used in the first 16 participants and 500 mg was used in the subsequent 16 participants.

    2023

  • Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis

    • Recreational drug use is a significant public health concern in various countries. It is well understood that usage of psychedelics/hallucinogens, such as lysergic acid diethylamide (LSD), ecstasy, phencyclidine (PCP), and psilocybin-containing mushrooms, has increased significantly over the last few decades, particularly in adolescents and young adults, yet the effects of these recreational drugs are poorly understood. Psilocybin has recently been studied as an alternative to traditional antidepressant therapies with potentially benign side effects.

    2023

  • Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial

    • Using a patient-informed regimen, we conducted an exploratory randomized, double-blind, placebo-controlled study to systematically investigate the effects of psilocybin in cluster headache.

    2022

  • Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation

    • Psilocybin (a serotonin 2A, or 5-HT2A, receptor agonist) has shown preliminary efficacy as a treatment for mood and substance use disorders. The current report utilized positron emission tomography (PET) with the selective 5-HT2A receptor inverse agonist radioligand [11C]MDL 100,907 (a.k.a. M100,907) and cortical regions of interest (ROIs) derived from resting-state functional connectivity-based brain parcellations in 4 healthy volunteers (2 females) to determine regional occupancy/target engagement of 5-HT2A receptors after oral administration of a psychoactive dose of psilocybin (10 mg/70 kg).

    2022

  • Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users—A National Survey Study

    • Hallucinogens are being explored as a potential treatment of psychiatric disorders. Micro dosing of illicitly purchased hallucinogen drugs is on the rise despite conclusive benefits. We aimed to evaluate the prevalence and odds of hopelessness, suicidality, and co-occurring substance use among adolescent hallucinogen users.

    2022

  • Psilocybin: From Serendipity to Credibility?

    • Psilocybin has a long history of non-medical use and some seem to infer from this that it has therapeutic utility. Early phase clinical trials with psilocybin are encouraging, but suggest only that larger, multicentre trials are required. These are ongoing but will take many years to complete. Meanwhile, retreat centers offering paid experiences with psilocybin truffles have opened in some countries, often using early phase clinical trial data as a basis for bold, public facing claims. This seems unwise. Early phase trials are not designed for their results to be generalized outside the setting they were undertaken in.

    2021

  • Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

    • While anecdotal evidence suggests that select 5-hydroxytryptamine 2A (5-HT2A) receptor ligands, including psilocybin, may have long-lasting therapeutic effects after limited dosing in headache disorders, controlled investigations are lacking. In an exploratory double-blind, placebo-controlled, cross-over study, adults with migraine received oral placebo and psilocybin (0.143 mg/kg) in 2 test sessions spaced 2 weeks apart. Subjects maintained headache diaries starting 2 weeks before the first session until 2 weeks after the second session. Physiological and psychological drug effects were monitored during sessions and several follow-up contacts with subjects were carried out to assure safety of study procedures.

    2021

  • A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

    • A single dose of psilocybin, a psychedelic and serotonin 2A receptor (5-HT2AR) agonist, may be associated with antidepressant effects. The mechanism behind its antidepressive action is unknown but could be linked to increased synaptogenesis and down-regulation of cerebral 5-HT2AR. Here, we investigate if a single psychedelic dose of psilocybin changes synaptic vesicle protein 2A (SV2A) and 5-HT2AR density in the pig brain. Twenty-four awake pigs received either 0.08 mg/kg psilocybin or saline intravenously.

    2021

  • Psychedelic medicine: The biology underlying the persisting psychedelic effects

    • Psychedelic substances have regained interest as therapeutic agents in the treatment of stress-related disorders. The effects seem to be of persisting nature even after a single dose. Also in lower than 'regular' recreational doses, so-called micro-doses, without the typical effects on consciousness, users report beneficial effects on cognitive processes and well-being. The exact neurobiological mechanism underlying these persisting effects is not clear. While previous research has mainly focused on the central nervous system including the immune system and the neuroendocrine system, I propose a central role for sleep and the microbiome in the effects of regular and low doses of psychedelics respectively.

    2019
▲show▼